Our findings that AXL mediates the oncogenic signaling of p85β provide further support for targeting AXL as a cancer treatment and suggest that PIK3R2 amplification could serve as a biomarker for the efficacy of AXL inhibitors. The gene discussed is AXL; the disease is cancer.